Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $2.63 USD
Change Today -0.08 / -2.95%
Volume 27.9K
As of 5:10 PM 11/27/15 All times are local (Market data is delayed by at least 15 minutes).

vbi vaccines inc (VBIV) Snapshot

Previous Close
Day High
Day Low
52 Week High
12/10/14 - $3.97
52 Week Low
09/30/15 - $1.94
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for VBI VACCINES INC (VBIV)

Related News

No related news articles were found.

vbi vaccines inc (VBIV) Related Businessweek News

No Related Businessweek News Found

vbi vaccines inc (VBIV) Details

VBI Vaccines Inc. operates as a biopharmaceutical company in the United States. It develops eVLP vaccine platform that allows for the design of enveloped (“e”) virus-like particle vaccines that closely mimic the target virus. The company’s lead eVLP asset is a prophylactic Cytomegalovirus (CMV) vaccine. It is also developing a thermostable technology platform that enables the development of vaccines and biologics that can withstand storage or shipment at constantly fluctuating temperatures. The company was formerly known as Paulson Capital (Delaware) Corp and changed its name to VBI Vaccines Inc. in July 2014. VBI Vaccines Inc. is headquartered in Cambridge, Massachusetts.

18 Employees
Last Reported Date: 03/20/15

vbi vaccines inc (VBIV) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $548.8K
Chief Financial Officer
Total Annual Compensation: $313.7K
Vice President of Formulations
Total Annual Compensation: $286.0K
Chief Scientific Officer
Total Annual Compensation: $334.1K
Compensation as of Fiscal Year 2014.

vbi vaccines inc (VBIV) Key Developments

SciVac Therapeutics Inc., VBI Vaccines Inc - M&A Call

To discuss the previously announced entry into merger agreement

VBI Vaccines Inc. and SciVac Therapeutics Inc. Announce Management Changes

VBI Vaccines Inc. and SciVac Therapeutics Inc. announced that they have entered into an agreement and plan of merger under which SciVac has agreed to acquire VBI to form a commercial-stage company. Pursuant to the agreement, a newly-formed wholly owned subsidiary of SciVac will merge with and into VBI, with VBI surviving the merger as a wholly owned subsidiary of SciVac, and SciVac will change its name to VBI Vaccines Inc. Jeff Baxter, VBI's president and chief executive officer, will be the president and chief executive officer of the combined company. VBI's chairman of the board, Dr. Steven Gillis, Ph.D., will serve as chairman of the board of the combined company and Dr. Curtis Lockshin, Ph.D., SciVac's chief executive officer, will assume the role of chief technical officer of the combined company.

VBI Vaccines Inc. Promotes David E. Anderson to Chief Scientific Officer

VBI Vaccines Inc. announced the promotion of Dr. David E. Anderson to Chief Scientific Officer. Dr. Anderson has led VBI's research and development activities since he joined the company full time in 2009 from Harvard Medical School, where he served as a member of the faculty.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VBIV:US $2.63 USD -0.08

VBIV Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for VBIV.
View Industry Companies

Industry Analysis


Industry Average

Valuation VBIV Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 146.2x
Price/Book 7.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 125.0x

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact VBI VACCINES INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at